StockNews.AI
FBLG
StockNews.AI
3 hrs

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

1. FibroBiologics' CSO will present at the Cell & Gene Meeting. 2. Presentation to focus on fibroblast technologies for unmet medical needs. 3. Clinical trial for diabetic foot ulcers planned for Q1 2026. 4. FibroBiologics holds over 270 patents related to chronic disease treatments.

6m saved
Insight
Article

FAQ

Why Bullish?

The announcement of trials and a notable industry presentation often boosts investor confidence. Historically, such events can positively impact stock prices, as seen in biotech firms after clinical trial announcements.

How important is it?

The article informs about key developments, which may indicate future revenue generation and investor enthusiasm. Such news is critical for a clinical-stage biotechnology firm like FBLG.

Why Short Term?

The upcoming presentation and trial initiation are expected to generate immediate investor interest. Short-term excitement often leads to price fluctuations based on news cycles.

Related Companies

PFEABBVAMGN
September 23, 2025 08:30 ET  | Source: FibroBiologics, Inc. HOUSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2025 Cell & Gene Meeting on the Mesa Conference taking place October 6-8 in Phoenix, Arizona. “The Cell & Gene Meeting on the Mesa provides an excellent opportunity to share updates on our fibroblast-based technologies and their potential to address unmet needs in several indications,” said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. “We look forward to providing continued updates as we advance our pipeline, including the initiation of our clinical trial for diabetic foot ulcers planned for the first quarter of 2026.” Details of the presentations are as follows: Event: 2025 Cell & Gene Meeting on the MesaSession Date and Time: October 7, 2025, at 2:15 p.m. MSTLocation: FLW Ballroom F For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com. Cautionary Statement Regarding Forward-Looking StatementsThis communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the anticipated timing of the initiation of, FibroBiologics’ clinical trials and research and development programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com. General Inquiries: info@fibrobiologics.com Investor Relations: Nic Johnson Russo Partners (212) 845-4242 fibrobiologicsIR@russopr.com Media Contact: Liz Phillips Russo Partners (347) 956-7697 Elizabeth.phillips@russopartnersllc.com

Related News